Search for: "Du Pont v. Du Pont"
Results 421 - 440
of 568
Sorted by Relevance
|
Sort by Date
5 Dec 2008, 11:26 pm
§ 312(a)(1), with the "substantial question of validity" standard by which a defendant may prevent a patentee from demonstrating a likelihood of success on the merits, see, e.g., E.I. du Pont de Nemours & Co. v. [read post]
26 Oct 2010, 8:59 pm
Leah Brannon and co-author Kathleen Bradish, both of Cleary Gottlieb Steen & Hamilton, offer a skeptical view: In the half-century since du Pont, lower courts have continued to view market definition as a predicate to Section 7 claims. [read post]
7 Aug 2023, 3:13 pm
A list of this week’s featured petitions is below: E.I. du Pont de Nemours & Co. v. [read post]
22 Sep 2011, 10:52 am
For example, in the E.I. du Pont de Nemours v. [read post]
20 Aug 2015, 3:56 am
KGaA v. [read post]
5 May 2020, 5:29 am
KGAA v. [read post]
18 Jan 2019, 4:16 am
Du Pont De Nemours & Co., 118 N.J.L. 404, 193 A. 194 (1937), aff'd 119 N.J.L. 427, 197 A. 276 (Err. [read post]
27 Aug 2014, 4:13 pm
I. du Pont de Nemours & Co., 476 F.2d 1357, 1361 (C.C.P.A. 1973). [read post]
11 May 2020, 4:01 am
Under the seventh and eight du Pont factors - and unlike the second, third, and fourth factors - the Board must consider any evidence of actual market conditions. [read post]
3 Oct 2015, 4:37 am
Precedential No. 20: 13th du Pont Factor Yields TTAB 2(d) ReversalTTAB Test: Which One of These Four Section 2(d) Refusals Was Reversed? [read post]
28 Jan 2020, 3:44 am
Although the involved services are related, the first du Pont factor, the dissimilarities between the marks, was dispositive. [read post]
23 May 2014, 2:26 pm
The Board conducted the likelihood of confusion analysis according to the thirteen factors set forth in the case In re E.I. du Pont Nemours & Co., 476 F.2d 1357, 1361 (C.C.P.A. 1973). [read post]
1 Apr 2010, 4:30 am
" Mars, for its part, appealed the verdict, arguing the trial court erred by qualifying Beauregarde as an expert under E.I. du Pont de Nemours & Co. v. [read post]
14 Jun 2017, 8:27 am
E.I. du Pont de Nemours & Co., 636 F.3d 88 (4th Cir. 2011), while the Ninth and Second Circuits had allowed such tactics. [read post]
19 Nov 2015, 7:48 pm
The Du Pont factors that are relevant to the record must be examined. [read post]
23 Apr 2009, 10:00 pm
(Spicy IP) India: Assessing India’s innovation climate (Biotech Blog) Kenya’s anti-counterfeit legislation, India protest (Afro-IP) Mexico: Pharmaceutical trade marks: the Health Law pitfall for applicants (International Law Office) US: BIO IP Counsels’ Committee: Q Todd Dickinson and E Anthony Figg on patent reform (Patent Docs) US: Amgen VP makes case for longer exclusivity period in follow-on biologics legislation (Patent Docs) Products Cepham –… [read post]
5 Dec 2019, 11:54 am
See E.I. du Pont de Nemours & Co., 803 F. [read post]
20 Sep 2013, 2:36 pm
Du Pont De Nemours & Co., 854 So.2d 1264, 1277 (Fla. 2003). [read post]
15 Aug 2011, 3:35 am
Of course, this du Pont factor weighed heavily in Nike's favor. [read post]
22 Oct 2015, 3:38 pm
The Board evaluated whether there was a likelihood of confusion by looking at the thirteen factors identified in In re E.I. du Pont de Nemours & Co., 476 F.2d 1357, 177 USPQ 563 (C.C.P.A. 1973). [read post]
